Cargando…
An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital
Pneumocystis jirovecii pneumonia (PCP) is associated with high mortality in immunocompromised patients without human immunodeficiency virus infection. However, chemoprophylaxis is highly effective. In patients with solid tumours or haematologic malignancy, several risk factors for developing PCP hav...
Autores principales: | Worth, L J, Dooley, M J, Seymour, J F, Mileshkin, L, Slavin, M A, Thursky, K A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361905/ https://www.ncbi.nlm.nih.gov/pubmed/15726101 http://dx.doi.org/10.1038/sj.bjc.6602412 |
Ejemplares similares
-
Pneumocystis jirovecii pneumonia following corticosteroid therapy
por: Garça, Magda, et al.
Publicado: (2023) -
Pneumocystis jirovecii pneumonia: a proposed novel model of corticosteroid benefit
por: Gharamti, Amal A., et al.
Publicado: (2021) -
Pneumocystis jirovecii pneumonia in developing countries
por: De Armas Rodríguez, Y., et al.
Publicado: (2011) -
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
por: Kuik, Kelvin Teck-Hong, et al.
Publicado: (2014) -
COVID-19 and Pneumocystis jirovecii pneumonia: Back to the basics
por: Mouren, D., et al.
Publicado: (2021)